Viewray Inc (NASDAQ:VRAY) – Analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for Viewray in a research report issued to clients and investors on Sunday. Cantor Fitzgerald analyst C. Bijou anticipates that the company will post earnings of ($1.03) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $13.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Viewray’s FY2018 earnings at ($0.59) EPS.
Viewray (NASDAQ:VRAY) last released its earnings results on Monday, November 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The business had revenue of $12.20 million for the quarter, compared to analyst estimates of $18.63 million. Viewray’s quarterly revenue was up 2950.0% on a year-over-year basis.
Shares of Viewray (NASDAQ:VRAY) opened at $10.12 on Wednesday. The firm has a market cap of $649.77, a P/E ratio of -9.28 and a beta of 17.60. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67. Viewray has a 52-week low of $3.01 and a 52-week high of $10.64.
Several hedge funds have recently made changes to their positions in VRAY. Schwab Charles Investment Management Inc. acquired a new stake in shares of Viewray during the 2nd quarter worth approximately $323,000. Rhumbline Advisers acquired a new stake in shares of Viewray during the 2nd quarter worth approximately $193,000. Bank of New York Mellon Corp grew its position in shares of Viewray by 146.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 109,348 shares of the company’s stock worth $707,000 after buying an additional 64,976 shares during the period. Alliancebernstein L.P. acquired a new stake in shares of Viewray during the 2nd quarter worth approximately $248,000. Finally, White Pine Capital LLC acquired a new stake in shares of Viewray during the 2nd quarter worth approximately $173,000. 50.02% of the stock is owned by institutional investors.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.